Nivolumab
Advanced or Metastatic Solid Tumor
Taiho Pharmaceutical Co., Ltd.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Advanced or Metastatic Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Futibatinib Taiho Pharmaceutical Co., Ltd. | Phase 2 | CCC |
Rogaratinib Bayer | Phase 1 | CC |
Inno-206 Bayer | Phase 1 | CC |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Bayer | Phase 1 | CC |
(+)-VINCRISTINE Taiho Pharmaceutical Co., Ltd. | Phase 1 | CC |
View all 27 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →